Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 25 Feb 2022 Disposal of own shares Read More 24 Feb 2022 2021 – Delivering on UCB’s Strategy and Commitments Read More 18 Feb 2022 Disposal of own shares Read More 11 Feb 2022 Disposal of own shares Read More 4 Feb 2022 Disposals of own shares Read More 4 Feb 2022 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results Read More Pagination First page Previous page Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
